- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01648556
Research of Predictive Factors to Immune Thrombopenic Purpura (PREDI-PTI)
Research of Predictive Factors to Immune Thrombopenic Purpura in Front of a Thrombopenia in Appearance Isolated in the Elderly
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
It is about a multicentric study prospective of more than patients' 60 years with a thrombopenia isolated of less than 100 G/L blood platelet without cause found to estimate so certain examinations realized in the diagnosis (medullary cytogenetics, dosage of the TPO, the Anti-platelet antibodies, isotopic lifetime of platelet) are in favour of the diagnosis of PTI.
The principal endpoint is to evaluate if the medullary cytogenetics is the predictive factor of the diagnosis of PTI in front of a thrombopenia isolated in elderly.
The secondary endpoints are :
- to identify at the time of the diagnosis, the factors and/or predictive markers correlated in the final diagnosis of PTI or SMD
to study the respective frequency of the PTI and the SMD in front of a thrombopenia seemingly isolated of the subject of more than 60 years.
200 patients will be included. 160 patients should be assessable at the end of study by considering the excluded patients, the dead and the lost sight.They will be followed every 4 months, during two years.
In every visit, will be realized a clinical examination, a blood film, a haemogram.
If the haemogram is abnormal, a bone marrow biopsy is realized. The patient who presents a myelodysplastic syndrome is excluded.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: JEAN PIERRE MAROLLEAU
- Phone Number: 00 33 33 45 59 14
- Email: marolleau.jean-pierre@chu-amiens.fr
Study Locations
-
-
-
Amiens, France, 80000
- Recruiting
- CHU Amiens
-
Contact:
- Jean Pierre MAROLLEAU, MD-PhD
-
Principal Investigator:
- Jean-Pierre MAROLLEAU, MD-PhD
-
Sub-Investigator:
- Bruno ROYER, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Rate of platelet < 100 G/l for less than 12 months ,
- age = ou > 60 years,
- haemoglobin > ou = 12 g / dl at the woman, > ou = 13 g/dl at the man,
- polymorphonuclear neutrophil > ou = 1.7 G/l,
- monocytes < ou= 1 G/l,
- lymphocytes < ou = à 4 G/l,
- VGM < 100 fL, blood film normal,
- informed consent,
- expectation of life > 6 months
Exclusion Criteria:
- hepatomegaly,
- splenomegaly,
- hepatic abnormality,
- blood coagulation abnormality,
- antecedent of auto-immune disease,
- drug thrombopenia,
- HIV, VHB or VHC positive,
- antecedent of malicious tumor in the 5 years before inclusion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: patients with a thrombopenia isolated
Patients of 60 years old and more presenting a thrombopenia isolated with a rate of platelet < 100 G/l Blood tests and bone marrow biopsy repeated
|
Blood tests are realized for the dosage of the TPO, the dosage of the antiplatelet antibodies, to measure isotopic lifetime of platelet. The test in corticoids by the prednisone per os is realized too. The bone marrow biopsy is realized at the inclusion and during follow-ups if the haemogram is abnormal.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the result of cytogenetics medullary
Time Frame: two years after inclusion
|
the primary endpoint corresponds to the occurence of the PTI after two years after inclusion.
|
two years after inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
dosage of the TPO
Time Frame: EVERY 4 MONTHS (followed every four months during two years apres inclusion)
|
EVERY 4 MONTHS (followed every four months during two years apres inclusion)
|
|
the result to the antibodies antiplatelet (positive or negative) for MAIPA
Time Frame: EVERY 4 MONTHS (followed every 4 months during two years after the inclusion)
|
EVERY 4 MONTHS (followed every 4 months during two years after the inclusion)
|
|
The isotopic lifetime of platelet
Time Frame: EVERY 4 MONTHS (followed every four months during two years apres inclusion)
|
< or > 3.5 days
|
EVERY 4 MONTHS (followed every four months during two years apres inclusion)
|
The test in corticoids by the prednisone per os
Time Frame: EVERY 4 MONTHS (followed every 4 months during two years after the inclusion)
|
1 mg / kg / day for 3 weeks The therapeutic test is considered as positive if a number of platelets is > 50 G/l with at least a doubling of the platelet rate before treatment
|
EVERY 4 MONTHS (followed every 4 months during two years after the inclusion)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jean Pierre MD MAROLLEAU, phD, CHU Amiens
- Principal Investigator: mathilde HUNAULT BERGER, Ph D, University Hospital, Angers
- Principal Investigator: NADINE MAGY BERTRAND, PH D, Centre Hospitalier Universitaire de Besançon
- Principal Investigator: Olivier FAIN, PH D, Hôpital Jean Verdier, Bondy
- Principal Investigator: BRIGITTE PAN PETESCH, D, CHU Brest
- Principal Investigator: MICHEL LEPORRIER, PH D, University Hospital, Caen
- Principal Investigator: BERTRAND GODEAU, PH D, CHU Créteil
- Principal Investigator: PHILIPPE BIERLING, PH D, EFS IVRY SUR SEINE
- Principal Investigator: LOUIS TERRIOU, PH D, CHRU Lille
- Principal Investigator: JEAN MARC DURAND, PH D, LA CONCEPTION MARSEILLE
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Hematologic Diseases
- Hemorrhage
- Blood Coagulation Disorders
- Skin Manifestations
- Thrombocytopenia
- Blood Platelet Disorders
- Thrombotic Microangiopathies
- Purpura
- Purpura, Thrombocytopenic
- Physiological Effects of Drugs
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Prednisone
Other Study ID Numbers
- PI2011_843_0002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Purpura Thrombopenic
-
Turkish Hematology AssociationSanofiRecruitingTTP - Thrombotic Thrombocytopenic PurpuraTurkey
-
University of CologneRecruitingAcquired Thrombotic Thrombocytopenic PurpuraGermany
-
Peking Union Medical College HospitalNot yet recruitingThrombotic Thrombocytopenic Purpura, AcquiredChina
-
Fundación Española de Hematología y HemoterapíaRecruitingAcquired Thrombotic Thrombocytopenic PurpuraSpain, Portugal
-
University of CologneRecruitingAcquired Thrombotic Thrombocytopenic PurpuraGermany
-
TakedaAvailableThrombotic Thrombocytopenic Purpura (TTP)
-
Ablynx, a Sanofi companyCompletedAcquired Thrombotic Thrombocytopenic PurpuraUnited States, Austria, Belgium, France, Germany, Israel, Italy, Spain, Switzerland, United Kingdom, Bulgaria, Romania, Australia
-
SanofiCompletedThrombotic Thrombocytopenic PurpuraJapan
-
SanofiCompletedAcquired Thrombotic Thrombocytopenic PurpuraUnited States, Austria, Belgium, Canada, Czechia, France, Hungary, Israel, Italy, Spain, Switzerland, Turkey, United Kingdom
-
Insel Gruppe AG, University Hospital BernSwiss National Science Foundation; Mach Gaensslen Foundation; Baxalta Innovations...RecruitingThrombotic Thrombocytopenic Purpura | Congenital Thrombotic Thrombocytopenic Purpura | Familial Thrombotic Thrombocytopenic Purpura | Thrombotic Thrombocytopenic Purpura, Congenital | Upshaw-Schulman SyndromeUnited States, Austria, Czechia, Germany, Japan, Norway, Switzerland
Clinical Trials on Blood tests and bone marrow biopsy repeated
-
Assiut UniversityNot yet recruitingMultiple Myeloma Survival Outcome
-
Gustave Roussy, Cancer Campus, Grand ParisRecruitingSolid Tumor, Adult | Solid Tumor, Childhood | Hematologic CancerFrance
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid System NeoplasmUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); National Institutes of Health (NIH)Enrolling by invitationLymphoproliferative Disorders | Myelodysplastic Syndromes | Myeloproliferative Disorders | Acute LeukemiaUnited States
-
Washington University School of MedicineRecruitingBreast NeoplasmsUnited States
-
Institut Paoli-CalmettesRecruitingMyelodysplastic Syndromes | Myeloproliferative Disorders | Acute LeukemiaFrance
-
Postgraduate Institute of Medical Education and...Completed
-
Medical College of WisconsinRecruitingBone Marrow Biopsy ProcedureUnited States
-
Duke UniversitySuspendedKidney Cancer | Prostate Cancer | Bladder Cancer | Genito Urinary CancerUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI); Incuron LLCRecruitingRefractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Recurrent Osteosarcoma | Refractory Osteosarcoma | Diffuse Midline Glioma, H3 K27M-Mutant | Recurrent Diffuse Intrinsic Pontine Glioma | Metastatic Malignant Neoplasm in the Central... and other conditionsUnited States